<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="letter" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Drugs</journal-id><journal-id journal-id-type="iso-abbrev">Drugs</journal-id><journal-id journal-id-type="pmc-domain-id">3814</journal-id><journal-id journal-id-type="pmc-domain">phenaturepg</journal-id><journal-title-group><journal-title>Drugs</journal-title></journal-title-group><issn pub-type="ppub">0012-6667</issn><issn pub-type="epub">1179-1950</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Springer Nature - PMC COVID-19 Collection</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10020758</article-id><article-id pub-id-type="pmcid-ver">PMC10020758.1</article-id><article-id pub-id-type="pmcaid">10020758</article-id><article-id pub-id-type="pmcaiid">10020758</article-id><article-id pub-id-type="doi">10.1007/s40265-023-01849-w</article-id><article-id pub-id-type="publisher-id">1849</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Letter to the Editor</subject></subj-group></article-categories><title-group><article-title>Comment on: &#8220;Risk of Erectile Dysfunction in Male Patients with Gout Treated with Febuxostat or Allopurinol: A Propensity Score-Matched Cohort Study&#8221;</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-5073-1205</contrib-id><name name-style="western"><surname>Huang</surname><given-names initials="JX">Jin-Xian</given-names></name><address><email>huangjx@hku-szh.org</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="GW">Guo-Wen</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.440671.0</institution-id><institution-id institution-id-type="ISNI">0000 0004 5373 5131</institution-id><institution>Department of Rheumatology, </institution><institution>The University of Hong Kong-Shenzhen Hospital, </institution></institution-wrap>Shenzhen, Guangdong China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.440671.0</institution-id><institution-id institution-id-type="ISNI">0000 0004 5373 5131</institution-id><institution>Department of Pathological Medicine, </institution><institution>The University of Hong Kong-Shenzhen Hospital, </institution></institution-wrap>Shenzhen, Guangdong China </aff></contrib-group><pub-date pub-type="epub"><day>17</day><month>3</month><year>2023</year></pub-date><pub-date pub-type="ppub"><year>2023</year></pub-date><volume>83</volume><issue>5</issue><issue-id pub-id-type="pmc-issue-id">431469</issue-id><fpage>461</fpage><lpage>463</lpage><history><date date-type="accepted"><day>14</day><month>2</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>17</day><month>03</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>17</day><month>03</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-02-15 00:25:12.480"><day>15</day><month>02</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s), under exclusive licence to Springer Nature Switzerland AG 2023</copyright-statement><license><license-p>This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="40265_2023_Article_1849.pdf"/><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="commentary" xml:lang="en" xlink:title="letter" journal-id="Drugs" journal-id-type="nlm-ta" ext-link-type="pmc" xlink:href="PMC10020747"><article-title>Authors&#8217; Reply to Huang and Zhang: Comment on &#8220;Risk of Erectile Dysfunction in Male Patients with Gout Treated with Febuxostat or Allopurinol: A Propensity Score-Matched Cohort Study&#8221;</article-title><volume>83</volume><issue>5</issue><date><day>17</day><month>3</month><year>2023</year></date><fpage>465</fpage><lpage>467</lpage><source>Drugs</source><pub-id pub-id-type="pmcid">PMC10020747</pub-id></related-article><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="commentary-article" xml:lang="en" journal-id="Drugs" journal-id-type="nlm-ta" ext-link-type="pubmed" xlink:href="36479686"><article-title>Risk of Erectile Dysfunction in Male Patients with Gout Treated with Febuxostat or Allopurinol: A Propensity Score-Matched Cohort Study.</article-title><date><day>7</day><month>12</month><year>2022</year></date><source>Drugs</source><pub-id pub-id-type="doi">10.1007/s40265-022-01816-x</pub-id><pub-id pub-id-type="pmid">36479686</pub-id></related-article><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Nature Switzerland AG 2023</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p id="Par1">Dear Editors</p><p id="Par2">We read with interest the article by Tong et al. [<xref ref-type="bibr" rid="CR1">1</xref>], which evaluated the risk of erectile dysfunction (ED) after urate lowering therapy (ULT) and favored allopurinol over febuxostat in male patients with gout via TriNetX database. Lacking consensus in current recommendations [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>], conclusions should be drawn with caution and would definitely influence future ULT selection for physician worldwide. We have several concerns on outcome measures, study design, coding, and confounders.</p><p id="Par3">First, the International Classification of Disease (ICD)-10 of ED (N52) applied in the study was incapable of distinction of ED classification. In a retrospective cohort study [<xref ref-type="bibr" rid="CR4">4</xref>] from the National Health Insurance Research Database (NHIRD) in Taiwan follow-up for 8 years, higher rates of atrial fibrillation were observed in impotence of organic origin ED (ICD-9-CM code 607.84) than those in psychosexual dysfunction (ICD-9-CM code 302.72) ED, indicating the role of endothelial dysfunction in disease pathophysiology. Subgroup analysis by ICD coding classification with organic ED and psychogenic ED accordingly would better interpret the statistical results. A disparate definition of &#8220;incident [<xref ref-type="bibr" rid="CR5">5</xref>], new onset [<xref ref-type="bibr" rid="CR6">6</xref>], and subsequent [<xref ref-type="bibr" rid="CR7">7</xref>]&#8221;, contrary to &#8220;recurrent and persistent&#8221; ED [<xref ref-type="bibr" rid="CR8">8</xref>], probably represented identical phenotype, is pending for further clarification and unification.</p><p id="Par4">As the main diagnostic endpoint of interest, the present study did not elaborate whether precise ED coding was conducted by excluding the prescription of phosphodiesterase-5&#160;inhibitors (PDEIs) including sildenafil, tadalafil, or vardenafil, vacuum constriction device and intracavernosal injection from Current Procedural Terminology (CPT) or Healthcare Common Procedural Coding System (HCPCS) codes [<xref ref-type="bibr" rid="CR9">9</xref>]. Without the 5-item version of the International Index of Erectile Function (IIEF-5) questionnaire for grading in the evaluation of ED severity, along with other ED assessments, e.g., Sexual Health Inventory for Men (SHIM), Erection Hardness Scale (EHS), penile doppler ultrasound and endothelial function [<xref ref-type="bibr" rid="CR10">10</xref>], stratification was impossible to judge the decision of ULT discontinuation. Tadalafil might be preferred over other PDEIs partially because of its longer half-life (17.5 h) and because it was associated with a decreased risk of major adverse cardiac events or venous thromboembolism [<xref ref-type="bibr" rid="CR11">11</xref>]. Retrieval of relevant information could help to identify the proportion of severe subjects on medication.</p><p id="Par5">Second, a time frame could be set before the Covid-19 epidemic attack in January 2020, owing to the association between Covid-19 infection (ICD-10-CM B34.2, U07.1, U07.2, J12.81, J12.82, B97.29)&#160;and new-onset ED, which was recently detected in the same database [<xref ref-type="bibr" rid="CR6">6</xref>]. The period selected between food and drug administration (FDA) approval for febuxostat and the awareness of potential drug-induced ED or FDA black box warning for cardiovascular disease (CVD) risk might also reduce selection bias.</p><p id="Par6">Besides, population enrollment within 12 months after ULT in the present study might be insufficient to reveal the therapeutic efficacy of drugs. Erectile dysfunction risk is significantly higher in patients with gout than in the general population incrementally in long-term observations over 10 years [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. A small cohort reported that hyperuricemia (HUA) was not an independent predictor of ED [<xref ref-type="bibr" rid="CR12">12</xref>]. Nonetheless, an not negligible&#160;high prevalence of ED in men with HUA has been identified in a recent meta-analysis from 8 studies [<xref ref-type="bibr" rid="CR13">13</xref>]. Furthermore, febuxostat was shown to have comparable effectiveness with allopurinol and demonstrated more potent performance in lowering serum uric acid (SUA) levels compared with allopurinol and eventually achieved more favorable renal outcome in those maintaining therapeutic targets in a 13-year inception cohort study [<xref ref-type="bibr" rid="CR14">14</xref>].</p><p id="Par7">In this study, patients treated with febuxostat had a higher percentage of chronic kidney disease (CKD) than those treated with allopurinol at baseline (29.6 % vs 18.8 %, Table 1), who were vulnerable to unmet or suboptimal SUA target. Patients taking febuxostat might be more aware of adverse effects of ED due to pre-existing drug information from physicians. The authors proposed the xanthine oxidase (XO)/xanthine dehydrogenase (XDH) ratio imbalance hypothesis in the contribution of febuxostat-triggered ED, while we recognized a descending trend in the survival curve (Fig. 2), with more prominent discrepancy after 120&#8211;180 days between allopurinol and febuxostat, suggesting the beneficial effect of febuxostat after tight control of SUA. With this accumulating evidence, we tend to believe that HUA instead of ULT in gout contributed to ED. Hyperuricemia is merely a marker in systemic dysmetabolic status triggering endothelial dysfunction, vasculopathy, eventually causing ED.</p><p id="Par8">According to the National Institute for Health and Care Excellence (NICE) guideline [<xref ref-type="bibr" rid="CR15">15</xref>], treat-to-target (T2T) approach should be adhered to with serum urate level of at least &lt;&#8201;360 &#956;mol/L. Cessation or tapering could only be considered in clinical remission taking ULT with no flares for &#8805;&#8201;1 year and no tophi. Although medication duration was not explicitly stated, up to over 10 years of observation was prevalent in previous studies [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. Since baseline SUA level, drug intensity and T2T timepoint was not available from the database, drug exposure could be prolonged to no less than 2 years for more convincing results.</p><p id="Par9">Third, sleep could be easily interrupted by gout attack or flares at night and sleep disorders (F51, G47), including insomnia (G47.0), sleep apnea (G47.3), or circadian rhythm dysfunction (G47.2), morbid obesity with alveolar hypoventilation (E66.2) and sleep deprivation (Z72.820) [<xref ref-type="bibr" rid="CR16">16</xref>&#8211;<xref ref-type="bibr" rid="CR18">18</xref>] should be included in the confounders. Bi-directional association has been reported between depression and sexual dysfunction. Major depressive disorder (F32&#8211;F33) [<xref ref-type="bibr" rid="CR5">5</xref>] instead of depression (F32) alone should be listed. Psychotic disorders (F20&#8211;F29), affective disorders (F30&#8211;F39), anxiety disorders (F40&#8211;48), substance use disorder (F10&#8211;F19), delirium (F05, R40.0, R41.0), dementia (F01-F03, G30, G31.0, G31.2, G31.83), and movement disorder (G20&#8211;G26) could also be considered in the analysis [<xref ref-type="bibr" rid="CR19">19</xref>]. After adjusting for the psychologic factors, the results would better reflect organic ED that is drug induced. Mitral Valve Prolapse (ICD-9&#8201;=&#8201;CM code 424.0) [<xref ref-type="bibr" rid="CR20">20</xref>] reported in another database could also be performed in propensity score matching.</p><p id="Par10">Finally, roughly implementing a cut-off age of 65 years might lead to important hints missing between 19 and 65 years. A subgroup analysis that is divided by age generations, similar to that in previous studies in ED [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR7">7</xref>], is highly anticipated to help the prescription choice in different age groups.</p><p id="Par11">In conclusion, febuxostat is a preferred choice of ULT, especially in Chinese gout patients with HLA-5801 positivity. Guidelines have agreed on a physician/patient-sharing decision-making strategy even in the situation of CVD comorbidities, regardless of ED. From our perspective, ED could be either organic due to uncontrolled endothelial dysfunction or psychologic partially attributed to individual fear of treatment. The former can be better improved by following T2T management and the latter could be cured by psychotherapy.</p></body><back><notes notes-type="data-availability"><title>Data availability</title><p>Not available.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="funding"><title>Funding</title><p id="Par12">No funding to declare.</p></notes><notes id="FPar2" notes-type="COI-statement"><title>Conflict of interest</title><p id="Par13">J-XH and G-WZ have no conflicts of interest that pertain to this letter.</p></notes><notes id="FPar3" notes-type="author-contribution"><title>Author contributions</title><p id="Par14">Both authors contributed equally to this letter.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tong</surname><given-names>Q</given-names></name><name name-style="western"><surname>Du</surname><given-names>Y</given-names></name><name name-style="western"><surname>Cui</surname><given-names>R</given-names></name><etal/></person-group><article-title>Risk of erectile dysfunction in male patients with gout treated with febuxostat or allopurinol: a propensity score-matched cohort study</article-title><source>Drugs</source><year>2022</year><volume>82</volume><issue>18</issue><fpage>1717</fpage><lpage>1726</lpage><pub-id pub-id-type="doi">10.1007/s40265-022-01816-x</pub-id><pub-id pub-id-type="pmid">36479686</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>FitzGerald</surname><given-names>JD</given-names></name><name name-style="western"><surname>Dalbeth</surname><given-names>N</given-names></name><name name-style="western"><surname>Mikuls</surname><given-names>T</given-names></name><etal/></person-group><article-title>2020 American College of Rheumatology Guideline for the management of gout</article-title><source>Arthritis Rheumatol</source><year>2020</year><volume>72</volume><issue>6</issue><fpage>879</fpage><lpage>895</lpage><pub-id pub-id-type="doi">10.1002/art.41247</pub-id><pub-id pub-id-type="pmid">32390306</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lorenzo</surname><given-names>JPP</given-names></name><name name-style="western"><surname>Sollano</surname><given-names>MHMZ</given-names></name><name name-style="western"><surname>Salido</surname><given-names>EO</given-names></name><etal/></person-group><article-title>2021 Asia-Pacific League of Associations for Rheumatology clinical practice guideline for treatment of gout</article-title><source>Int J Rheum Dis</source><year>2022</year><volume>25</volume><issue>1</issue><fpage>7</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1111/1756-185X.14266</pub-id><pub-id pub-id-type="pmid">34931463</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>KL</given-names></name><name name-style="western"><surname>Ye</surname><given-names>LL</given-names></name><name name-style="western"><surname>Chou</surname><given-names>SH</given-names></name><etal/></person-group><article-title>Erectile dysfunction is not a predictor of atrial fibrillation: a population-based propensity-score matched cohort study</article-title><source>J Sex Med</source><year>2016</year><volume>13</volume><issue>1</issue><fpage>55</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1016/j.jsxm.2015.11.010</pub-id><pub-id pub-id-type="pmid">26755087</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schlesinger</surname><given-names>N</given-names></name><name name-style="western"><surname>Lu</surname><given-names>N</given-names></name><name name-style="western"><surname>Choi</surname><given-names>HK</given-names></name></person-group><article-title>Gout and the risk of incident erectile dysfunction: a body mass index-matched population-based study</article-title><source>J Rheumatol</source><year>2018</year><volume>45</volume><issue>8</issue><fpage>1192</fpage><lpage>1197</lpage><pub-id pub-id-type="doi">10.3899/jrheum.170444</pub-id><pub-id pub-id-type="pmid">30008453</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chu</surname><given-names>KY</given-names></name><name name-style="western"><surname>Nackeeran</surname><given-names>S</given-names></name><name name-style="western"><surname>Horodyski</surname><given-names>L</given-names></name><etal/></person-group><article-title>COVID-19 infection is associated with new onset erectile dysfunction: insights from a National Registry</article-title><source>Sex Med</source><year>2022</year><volume>10</volume><issue>1</issue><fpage>100478</fpage><pub-id pub-id-type="doi">10.1016/j.esxm.2021.100478</pub-id><pub-id pub-id-type="pmid">34931145</pub-id><pub-id pub-id-type="pmcid">PMC8673874</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>YF</given-names></name><name name-style="western"><surname>Lin</surname><given-names>HH</given-names></name><name name-style="western"><surname>Lu</surname><given-names>CC</given-names></name><etal/></person-group><article-title>Gout and a subsequent increased risk of erectile dysfunction in men aged 64 and under: a nationwide cohort study in Taiwan</article-title><source>J Rheumatol</source><year>2015</year><volume>42</volume><issue>10</issue><fpage>1898</fpage><lpage>1905</lpage><pub-id pub-id-type="doi">10.3899/jrheum.141105</pub-id><pub-id pub-id-type="pmid">26077405</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mazzilli</surname><given-names>F</given-names></name></person-group><article-title>Erectile dysfunction: causes, diagnosis and treatment: an update</article-title><source>J Clin Med</source><year>2022</year><volume>11</volume><issue>21</issue><fpage>6429</fpage><pub-id pub-id-type="doi">10.3390/jcm11216429</pub-id><pub-id pub-id-type="pmid">36362656</pub-id><pub-id pub-id-type="pmcid">PMC9657711</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nackeeran</surname><given-names>S</given-names></name><name name-style="western"><surname>Havanur</surname><given-names>A</given-names></name><name name-style="western"><surname>Ory</surname><given-names>J</given-names></name><etal/></person-group><article-title>Erectile dysfunction is a modifiable risk factor for major depressive disorder: analysis of a federated research network</article-title><source>J Sex Med</source><year>2021</year><volume>18</volume><issue>12</issue><fpage>2005</fpage><lpage>2011</lpage><pub-id pub-id-type="doi">10.1016/j.jsxm.2021.09.016</pub-id><pub-id pub-id-type="pmid">34857255</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="other">Saltzman RG, Golan R, Masterson TA 3rd, et al. Restorative therapy clinical trials for erectile dysfunction: a scoping review of endpoint measures. Int J Impot Res. 2022. 10.1038/s41443-022-00610-3.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41443-022-00610-3</pub-id><pub-id pub-id-type="pmid">36068326</pub-id></mixed-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goberdhan</surname><given-names>S</given-names></name><name name-style="western"><surname>Blachman-Braun</surname><given-names>R</given-names></name><name name-style="western"><surname>Nackeeran</surname><given-names>S</given-names></name><etal/></person-group><article-title>Is tadalafil associated with decreased risk of major adverse cardiac events or venous thromboembolism in men with lower urinary tract symptoms?</article-title><source>World J Urol</source><year>2022</year><volume>40</volume><issue>7</issue><fpage>1799</fpage><lpage>1803</lpage><pub-id pub-id-type="doi">10.1007/s00345-022-04005-3</pub-id><pub-id pub-id-type="pmid">35469100</pub-id><pub-id pub-id-type="pmcid">PMC9037966</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tuokko</surname><given-names>AT</given-names></name><name name-style="western"><surname>Murtola</surname><given-names>T</given-names></name><name name-style="western"><surname>Korhonen</surname><given-names>P</given-names></name><etal/></person-group><article-title>Hyperuricemia is not an independent predictor of erectile dysfunction</article-title><source>Sex Med</source><year>2021</year><volume>9</volume><issue>2</issue><fpage>100319</fpage><pub-id pub-id-type="doi">10.1016/j.esxm.2020.100319</pub-id><pub-id pub-id-type="pmid">33621708</pub-id><pub-id pub-id-type="pmcid">PMC8072167</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Totaro</surname><given-names>M</given-names></name><name name-style="western"><surname>Dimarakis</surname><given-names>S</given-names></name><name name-style="western"><surname>Castellini</surname><given-names>C</given-names></name><etal/></person-group><article-title>Erectile dysfunction in hyperuricemia: a prevalence meta-analysis and meta-regression study</article-title><source>Andrology</source><year>2022</year><volume>10</volume><issue>1</issue><fpage>72</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1111/andr.13088</pub-id><pub-id pub-id-type="pmid">34347943</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chou</surname><given-names>HW</given-names></name><name name-style="western"><surname>Chiu</surname><given-names>HT</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>CW</given-names></name><etal/></person-group><article-title>Comparative effectiveness of allopurinol, febuxostat and benzbromarone on renal function in chronic kidney disease patients with hyperuricemia: a 13-year inception cohort study</article-title><source>Nephrol Dial Transplant</source><year>2018</year><volume>33</volume><issue>9</issue><fpage>1620</fpage><lpage>1627</lpage><pub-id pub-id-type="pmid">29165620</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ndt/gfx313</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neilson</surname><given-names>J</given-names></name><name name-style="western"><surname>Bonnon</surname><given-names>A</given-names></name><name name-style="western"><surname>Dickson</surname><given-names>A</given-names></name><etal/></person-group><article-title>Gout: diagnosis and management-summary of NICE guidance</article-title><source>BMJ</source><year>2022</year><volume>378</volume><fpage>o1754</fpage><pub-id pub-id-type="doi">10.1136/bmj.o1754</pub-id><pub-id pub-id-type="pmid">36041743</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="other">Agrawal P, Singh SM, Able C, et al. Sleep disorders are associated with testosterone deficiency and erectile dysfunction-a U.S. claims database analysis. Int J Impot Res. 2022. 10.1038/s41443-022-00649-2.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41443-022-00649-2</pub-id><pub-id pub-id-type="pmid">36473958</pub-id></mixed-citation></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="other">Agrawal P, Singh SM, Kohn J, et al. Sleep disorders are associated with female sexual desire and genital response&#8212;a U.S. claims database analysis. Urology. 2023:172:79&#8211;83. 10.1016/j.urology.2022.11.017.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.urology.2022.11.017</pub-id><pub-id pub-id-type="pmid">36455681</pub-id></mixed-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cantone</surname><given-names>E</given-names></name><name name-style="western"><surname>Massanova</surname><given-names>M</given-names></name><name name-style="western"><surname>Crocetto</surname><given-names>F</given-names></name><etal/></person-group><article-title>The relationship between obstructive sleep apnoea and erectile dysfunction: an underdiagnosed link? A prospective cross-sectional study</article-title><source>Andrologia</source><year>2022</year><volume>54</volume><issue>9</issue><fpage>e14504</fpage><pub-id pub-id-type="doi">10.1111/and.14504</pub-id><pub-id pub-id-type="pmid">35817418</pub-id><pub-id pub-id-type="pmcid">PMC9539465</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Colbourne</surname><given-names>L</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>PJ</given-names></name></person-group><article-title>Brain-penetrant calcium channel blockers are associated with a reduced incidence of neuropsychiatric disorders</article-title><source>Mol Psychiatry</source><year>2022</year><volume>27</volume><issue>9</issue><fpage>3904</fpage><lpage>3912</lpage><pub-id pub-id-type="doi">10.1038/s41380-022-01615-6</pub-id><pub-id pub-id-type="pmid">35618884</pub-id><pub-id pub-id-type="pmcid">PMC9708561</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chung</surname><given-names>SD</given-names></name><name name-style="western"><surname>Liu</surname><given-names>JC</given-names></name><name name-style="western"><surname>Lou</surname><given-names>TN</given-names></name><etal/></person-group><article-title>Relation between mitral valve prolapse and erectile dysfunction (from a nationwide case-control study)</article-title><source>Am J Cardiol</source><year>2019</year><volume>124</volume><issue>10</issue><fpage>1590</fpage><lpage>1593</lpage><pub-id pub-id-type="doi">10.1016/j.amjcard.2019.08.010</pub-id><pub-id pub-id-type="pmid">31514966</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>